Valeant has drawn scrutiny from Congress, hospitals and patients for sharply increasing their prices, the NYT reports.» Read More
Valeant stock has crumbled amid multiple probes over its relationship with a specialty pharmacy, the Financial Times reports.
Peter Toogood, investment director at City Financial Investment Company Limited, explains why large pharmaceuticals tend to take over midcap rivals.
Pershing Square's Bill Ackman has sent a letter to Valeant Chairman and CEO Michael Pearson, expressing support of his leadership.
CNBC's Dina Gusovsky provides insight to the investigation into Insys Therapeutics and its business and marketing practices. The company sells an opiate called Subsys Fentanyl Sublingual Spray.
Michael Babich, CEO of Insys Therapeutics, which is subject to several state and federal inquiries about its painkiller Subsys, is out.
Robert Mulroy, Merrimack CEO, discusses the risk factors and time element it takes to create innovative drugs as R&D costs rise and pharma consolidation continues.
The Turing Pharmaceuticals CEO says that the price increase of the drug Daraprim won't affect overall prescription cost trends.
Lawmakers are responding to the public outcry over spiking drug prices, reports CNBC's Meg Tirrell.
Turing Pharmaceuticals said it would lower the price by the end of the year and take steps to broaden financial support to patients, the NYT reports.
GlaxoSmithKline CEO Sir Andrew Witty weighs in on why his company has no immediate deal plans in the drug space.
Philidor, a pharmacy facing backlash from accusations about Valeant Pharmaceuticals' business model, announced it would close.
CNBC's Meg Tirrell looks at what's happened to Valeant shares over the last month. The company's stock is down nearly 50 percent since a short-seller linked the stock to Enron.
A teenaged girl in Oregon has been diagnosed with the bubonic plague, which she may have contracted from a flea bite.
Pershing Square Capital's Bill Ackman said Valeant Pharmaceuticals made a mistake by underinvesting in public, government, and investor relations.
Valeant said it is terminating all ties with Philidor due to allegations relating to the specialty pharmacy distributor's business practices.
Shares of Valeant plunged as some benefits managers began cutting off business with a pharmacy associated with Valeant.
CNBC Senior Markets Commentator Michael Santoli discusses why a deal with Allergan makes sense for Pfizer.
Thornburg Investment Manager Connor Browne discusses why there could be more M&A activity in the health care space as the election cycle heats up.
A possible deal between Ireland-based Allergan and U.S. drugmaker Pfizer raises questions about another pharmaceutical tax inversion.
Jesper Brandgaard, CFO and executive vice-president at Novo Nordisk, says he is optimistic about Tresiba, a next-generation diabetes treatment coming to the market.
Get the best of CNBC in your inbox